Markets

Neurocrine Biosciences, Inc. Enters Oversold Territory - Tale of the Tape

Neurocrine Biosciences, Inc.'s ( NBIX ) share price has entered into oversold territory with an RSI value of 26.0. The Zacks Consensus Estimate on Neurocrine Biosciences, Inc.'s earnings for the full year period has loss of 0.08 cents over the past two months to $0.70 per share. Currently, Neurocrine Biosciences, Inc. is a Zacks #2 Rank ("Buy"), suggesting that now might be a good time to get in on ( NBIX ) after its recent drop.

NEUROCRINE BIOS (NBIX): Get Free Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

NBIX

Other Topics

Investing Stocks

Latest Markets Videos